Sarepta Therapeutics
SRPT
404 hedge funds and large institutions have $9.38B invested in Sarepta Therapeutics in 2023 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 150 increasing their positions, 126 reducing their positions, and 78 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 126
4.39% less ownership
Funds ownership: 92.32% → 87.92% (-4.4%)
5% less funds holding
Funds holding: 425 → 404 (-21)
16% less capital invested
Capital invested by funds: $11.2B → $9.38B (-$1.81B)
24% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 78
31% less call options, than puts
Call options by funds: $276M | Put options by funds: $402M
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$126M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$119M |
| 3 |
JP Morgan Chase
New York
|
+$90.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$85.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$82.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$108M |
| 3 |
D.E. Shaw & Co
New York
|
-$74.4M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$66.7M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$57.6M |
SRPT Hedge Fund Activity: Q2 2023 in Review
404 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2023, worth a combined $9.38B — down 16% from $11.2B a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of SRPT and 59 opened new positions — a net loss of 19 holders — while 126 trimmed existing stakes and 150 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $126M. The largest seller was Sands Capital Management, exiting entirely with an estimated $121M sold.
- 404 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2023, down from 425 in Q1 2023.
- Funds reported $9.38B of Sarepta Therapeutics stock for Q2 2023, down 16% quarter-over-quarter.
- 59 funds opened new Sarepta Therapeutics positions in Q2 2023 and 78 closed out, a net change of -19 holders.
- The largest Sarepta Therapeutics buyer in Q2 2023 was Avoro Capital Advisors, an estimated $126M added.
- The largest Sarepta Therapeutics seller in Q2 2023 was Sands Capital Management, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2023.